Immunogenicity Study of the Covid-19 (Recombinante) Vaccine With a 4 or 8 Week Interval Between the First Doses.

NCT ID: NCT05157178

Last Updated: 2023-06-13

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 1264 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-07-20
• Study Completion Date: 2023-06-30

Brief Summary

The purpose of this clinical trial is to compare antibody response and safety of the Covid-19 (recombinante) vaccine according to different time intervals between the first two doses (4, 8 and 12 weeks) and serologic status immediately before the vaccine.

Detailed Description

After being informed about the study and potential risks, all participants giving written informed consent will be evaluated for eligibility criteria. At day 0, participants who meet the eligibility requirements will undergo a thorough medical evaluation and a urine pregnancy test (if applicable). Eligible participants will be placed in one of three vaccination interval groups (4, 8 or 12 weeks between the first two Covid -19 (recombinante) vaccine doses) in a randomized manner, via a computer program created by the statistical annalist. Both participant and research team will know the allocated group.

Eligible and consenting participants will have a blood sample collected (IgG Anti-S antibodies) and immediately after be administered a third dose of the Covid-19 (recombinante) vaccine. Participants will be instructed to fill out an adverse events journal for solicited adverse events for 7 days and non-solicited adverse events for 28 days after each dose. The research team will contact the participant remotely at least twice during the first two weeks.

The participant will return for a follow-up visit to the research center 28 days after each dose, to evaluate adverse events, collect blood samples (IgG Anti-S antibodies) and undergo a thorough medical evaluation.

The participant will also return to the research center to collect blood samples (IgG Anti-S antibodies) in two more follow-up visits: 6 and 12 months after vaccination with Covid-19 (recombinante).

Conditions

COVID-19

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

4 week interval

Administration of two doses of the Covid-19 (recombinante) vaccine, with a 4 week interval between the two doses.

Group Type: EXPERIMENTAL

Covid-19 (recombinante) vaccine

Intervention Type: BIOLOGICAL

Administration of the Covid-19 (recombinante) vaccine

8 week interval

Administration of two doses of the Covid-19 (recombinante) vaccine, with a 8 week interval between the two doses.

Group Type: EXPERIMENTAL

Covid-19 (recombinante) vaccine

Intervention Type: BIOLOGICAL

Administration of the Covid-19 (recombinante) vaccine

12 week interval

Administration of two doses of the Covid-19 (recombinante) vaccine, with a 12 week interval between the two doses.

Group Type: ACTIVE_COMPARATOR

Covid-19 (recombinante) vaccine

Intervention Type: BIOLOGICAL

Administration of the Covid-19 (recombinante) vaccine

Interventions

Covid-19 (recombinante) vaccine

Administration of the Covid-19 (recombinante) vaccine

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Availability to participate during the entire study, and ability to follow study protocol strictly.
• Consent to supply personal contact information, such as telephone numbers, address and other information so the research team may contact the participant (For example, in case the participant fails to attend a scheduled visit without previous notice)
• Ability to understand and sign the volunteered and informed consent form, and ability to fill in the adverse events journal at home, according to the evaluation of the principal investigator ou delegated research team members.
• Understanding the impossibility of participating in another clinical trial while participating in this clinical trial.
• Ability to fill out the adverse events journal at home

Exclusion Criteria

• Pregnancy or puerperium
• Having received any other Covid-19 vaccine any time before inclusion in the study
• Having received any other vaccine 30 days before inclusion in the study
• Covid-19 disease confirmed by RT-PCR (Real time polymerase chain reaction) up to 28 days before inclusion in the study.
• Covid-19 symptoms during evaluation of inclusion in the study (Day 0).
• Fever (Axillary temperature above 37,8 º C / 100,04 °F) 72 hours before vaccination in the study.
• Contraindications to the Covid-19 (recombinante) vaccine - Fiocruz/AstraZeneca
• Use of immunosuppressive medication, such as systemic corticosteroids or chemotherapy, or immunosuppressive diseases. We will consider as immunosuppressive doses of systemic corticosteroids daily doses of prednisone of 10mg or more, for more than 14 days.
• Any discoveries made by the principal investigator that would enhance the risk of an adverse result following the participation in the study, or that in some other way justifies exclusion from the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clarice Monteiro Vianna

Role: PRINCIPAL_INVESTIGATOR

Bio-Manguinhos/Fiocruz

Locations

Instituto de Tecnologia do Paraná (TECPAR)

Curitiba, Paraná, Brazil

Hospital Universitário Pedro Ernesto/ UERJ

Rio de Janeiro, , Brazil

Policlinica Lincoln de Freitas Filho

Rio de Janeiro, , Brazil

Unidade de Ensaios Clínicos em Imunobiológicos

Rio de Janeiro, , Brazil

Countries

Brazil

Other Identifiers

ASCLIN 004/2021

Identifier Type: -

Identifier Source: org_study_id